ABT Abbott Laboratories - Fundamental Analysis
NEUTRAL
ABT Stock | Fundamental Analysis & Investment Insights
NYSE
•
Healthcare
•
Medical Devices
Current Price
$130.59
Analyst Target
$144.47
+10.6% Upside
52W High
$141.23
52W Low
$110.86
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
Abbott Laboratories trades at $130.59, near its 52-week range midpoint, with solid long-term price appreciation (25.7% over 5Y) but recent underperformance (down 2.3% over 6M). The company exhibits strong profitability—ROE of 30.62%, gross margin of 56.26%, and a lean debt/equity of 0.25—yet faces near-term stagnation in earnings growth (0.0% YoY) and a concerning lack of earnings beats over the last four quarters. Valuation appears stretched relative to fundamentals, with a forward P/E of 25.31 significantly above its trailing P/E of 16.39 and peer average P/E of 23.18. Analysts maintain a 'buy' recommendation with a $144.47 target, implying 10.6% upside, but insider selling and flat earnings momentum temper near-term conviction.
Key Strengths
Exceptional profitability with ROE of 30.62%, outperforming sector average (29.25%) and peers like BMRN (9.07%) and BNTX (-3.04%)
Industry-leading profit margin of 31.88% versus sector average of 6.05%, reflecting pricing power and cost discipline
Conservative capital structure with debt/equity of 0.25, well below sector average of 1.93 and peers like AMGN (5.67)
Strong liquidity position: current ratio of 1.70 and quick ratio of 1.09, indicating robust short-term financial flexibility
Attractive dividend profile with 1.81% yield and low payout ratio of 29.15%, signaling sustainable capital return
Key Risks
Earnings growth at 0.0% YoY and Q/Q decline of -0.10%, indicating profit stagnation despite 6.9% revenue growth
Forward P/E of 25.31 is elevated relative to trailing P/E of 16.39, suggesting over-optimism in growth expectations
No earnings beat in the last four quarters, signaling potential guidance tightening or execution slippage
Insider selling activity: CFO sold $0.75M in shares, a bearish signal from management amid stretched valuation
Revenue growth of 6.9% lags peer average of 12.83%, with AMGN (12.4%) and BNTX (22.0%) showing stronger top-line momentum
AI Fair Value Estimate
Based on comprehensive analysis
$138.5
+6.1% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare ABT against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations